Brokerages predict that Humana Inc (NYSE:HUM) will announce sales of $14.12 billion for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Humana’s earnings, with estimates ranging from $13.96 billion to $14.32 billion. Humana posted sales of $13.76 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 2.6%. The firm is expected to report its next quarterly earnings results on Wednesday, May 2nd.
According to Zacks, analysts expect that Humana will report full-year sales of $14.12 billion for the current financial year, with estimates ranging from $55.63 billion to $56.19 billion. For the next year, analysts anticipate that the business will post sales of $59.97 billion per share, with estimates ranging from $59.07 billion to $60.65 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Humana.
Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, beating the consensus estimate of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The company had revenue of $13.19 billion for the quarter, compared to analyst estimates of $13.14 billion. During the same period in the prior year, the company posted $2.34 EPS. The company’s revenue was up 2.4% compared to the same quarter last year.
HUM has been the topic of several analyst reports. Leerink Swann upped their price objective on Humana from $280.00 to $300.00 and gave the company an “outperform” rating in a research note on Thursday, February 8th. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $297.00 price objective on the stock in a research note on Monday, January 15th. Credit Suisse Group lowered their price objective on Humana from $256.00 to $246.00 and set a “neutral” rating on the stock in a research note on Friday, November 10th. ValuEngine lowered Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $250.00 price objective on shares of Humana in a research note on Wednesday, February 7th. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $270.47.
Shares of Humana (NYSE HUM) opened at $269.00 on Monday. Humana has a 12 month low of $203.36 and a 12 month high of $293.35. The firm has a market capitalization of $37,037.08, a P/E ratio of 16.13, a PEG ratio of 1.45 and a beta of 0.93. The company has a quick ratio of 1.61, a current ratio of 1.85 and a debt-to-equity ratio of 0.48.
Humana declared that its board has initiated a stock repurchase program on Thursday, December 14th that permits the company to buyback $3.00 billion in outstanding shares. This buyback authorization permits the insurance provider to buy shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be issued a dividend of $0.50 per share. This is an increase from Humana’s previous quarterly dividend of $0.40. The ex-dividend date is Wednesday, March 28th. This represents a $2.00 annualized dividend and a yield of 0.74%. Humana’s dividend payout ratio is currently 9.59%.
In other Humana news, VP Timothy S. Huval sold 1,382 shares of the company’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total transaction of $340,027.28. Following the transaction, the vice president now owns 11,557 shares of the company’s stock, valued at approximately $2,843,484.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Jody L. Bilney sold 7,054 shares of the company’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $247.89, for a total value of $1,748,616.06. Following the transaction, the senior vice president now directly owns 11,704 shares in the company, valued at approximately $2,901,304.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,115 shares of company stock worth $2,501,627. Company insiders own 0.80% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Janus Henderson Group PLC lifted its holdings in Humana by 74.1% during the 3rd quarter. Janus Henderson Group PLC now owns 2,729,248 shares of the insurance provider’s stock worth $664,921,000 after buying an additional 1,161,661 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Humana by 11.4% during the 4th quarter. Wells Fargo & Company MN now owns 1,842,029 shares of the insurance provider’s stock worth $456,951,000 after buying an additional 188,711 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Humana by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 1,522,654 shares of the insurance provider’s stock worth $376,937,000 after buying an additional 28,147 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in Humana by 10.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,465,119 shares of the insurance provider’s stock worth $356,960,000 after buying an additional 142,706 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in Humana by 3.0% during the 4th quarter. Acadian Asset Management LLC now owns 1,043,303 shares of the insurance provider’s stock worth $258,809,000 after buying an additional 30,812 shares in the last quarter. 97.68% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “$14.12 Billion in Sales Expected for Humana Inc (HUM) This Quarter” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/19/14-12-billion-in-sales-expected-for-humana-inc-hum-this-quarter.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Get a free copy of the Zacks research report on Humana (HUM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.